National Center for PTSD
13
6
6
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
15.4%
2 terminated/withdrawn out of 13 trials
66.7%
-19.8% vs industry average
8%
1 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Role: collaborator
mHealth Estimate-based Algorithms Signaling Upcoming Recurrence of Episodes in Bipolar Disorders
Role: collaborator
MDMA-assisted Massed Prolonged Exposure for PTSD
Role: collaborator
rTMS-augmented Written Exposure Therapy for PTSD
Role: collaborator
COPEWeb Training for Providers
Role: collaborator
Trauma Informed Guilt Reduction Therapy
Role: collaborator
Mechanisms Underlying the Efficacy of Prolonged Exposure
Role: collaborator
Mobile Mindfulness for Alcohol Use and PTSD Among Veterans
Role: collaborator
Sustaining and Improving Clinicians' Use of Evidence-Based Psychotherapy (EBP) for PTSD
Role: collaborator
Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)
Role: collaborator
Oxytocin and Affect Processing in Posttraumatic Stress Disorder
Role: collaborator
A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)
Role: collaborator
Mobile Apps for the Treatment of Depression
Role: collaborator
All 13 trials loaded